看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
4 ?7 M! z( w: X. [1 B
4 A5 E' s& t D/ d/ f
) s3 s$ e7 c& o4 j/ I) y+ SCurrently available feasibility data for possible combination strategies.
, O4 q) w7 n) g$ @————————————————————————————————5 p. ]8 W; B, N \8 t
Combination Feasibility according to preliminary data
, S; q1 K9 |% e4 B) S+ v——————————————————————————————————; c/ O6 s+ t g n8 D- }
Bevacizumab + sorafenib Yes, reduced dose $ R t) T" B3 J8 h2 a
Bevacizumab + sunitinib† No
! O% A$ d6 J2 L) ]: J8 z- f EBevacizumab + temsirolimus Yes
: f& O) m& l pBevacizumab + everolimus Yes $ d# k' x* |% z2 \& R6 A/ {
Sorafenib + sunitinib ? ?4 m; Y6 k c, {+ ]5 H% l7 r8 ~
Sorafenib + temsirolimus Yes, reduced dose u( ]$ ^& B& J" ]" P( K" b
Sorafenib + everolimus Yes, reduced dose + g; M: n$ O6 I0 x1 T% O( d
Sunitinib + temsirolimus† No ) o' I3 S: r* {$ `+ [' F
Sunitinib + everolimus ?
0 v+ Z1 h% K8 n$ q: S6 ~; JTemsirolimus + everolimus ?
, A4 Q: Y& [$ ~" I& P9 k" w————————————————————( d* J, d# O6 U9 s: z
†Led to US FDA warning.2 L. e$ A& i. Q7 [- P. e) f8 i
?: As yet unattempted combination.
6 ?$ ^ T T, G6 ~ |
显身卡
